Uploaded September 2026 | Updated September 2026, 2 weeks ago

---

The EpiSwitch PSE test is being promoted as a major advance in prostate cancer risk assessment, but how does it actually compare with PSA?

Dr. Stephen Petteruti examines what the test can tell you, its limitations, its cost, and why he believes PSA still has an important advantage when prostate cancer risk needs to be monitored over time.

Watch the full episode of Intellectual Medicine for the complete discussion.

#ProstateCancer #PSATest #EpiSwitch #ProstateHealth #MensHealth #CancerScreening #IntellectualMedicine #DrStephenPetteruti